Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCXH-211 in recurrent or progressive high-grade glioma
NCT06468605Phase 1Withdrawn
- Sponsor
- Duke University
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of JCXH-211 in glioma, sponsored by Duke University. Primary endpoint: Maximum Tolerated Dose or Recommended Phase 2 Dose. Planned start Nov 2025; status: withdrawn.
02
Drugs
JCXH-211
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06468605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468605.